Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data

The WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group*

Abstract

Background: Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia.

Methods: Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall \( \geq 25\% \) at day 3 and day 7.

Results: A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0–19.7 g/dL) in Africa, 11.6 g/dL (range 5.0–20.0 g/dL) in Asia and 12.3 g/dL (range 6.9–17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7 g/dL) was present in 8.4\% (4284/50,859) of patients from Africa, 3.3\% (606/18,451) from Asia and 0.1\% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to \( \geq 12 \) years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39–3.05], \( p < 0.001 \)).

Conclusions: In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.
Keywords: *Plasmodium falciparum*, Artemisinin-based therapy, Non-artemisinin-based therapy, Antimalarials, Haemoglobin, Severe anaemia, Pooled analysis of individual patient data

**Background**

Malaria remains a major cause of anaemia in malaria endemic countries, with a complex pathogenesis attributable to red cell destruction and haematopoietic suppression [1] that can be compounded by malnutrition, helminth carriage and inherited blood disorders [2]. Artemisinin-based combination therapy (ACT) is the first-line antimalarial treatment for uncomplicated malaria in almost all endemic countries [3], achieving high cure rates, rapid parasite clearance and reduced ongoing transmission of the parasite [4, 5]. However, artemisinin derivatives can suppress reticulocytosis and contribute to haemolysis; their use has been associated with delayed-onset anaemia [6, 7]. The haematological recovery and adverse consequences of the artemisinin derivatives, following the treatment of falciparum malaria, may vary between different ACTs [8].

To assess the comparative benefits of different antimalarial treatment regimens, it is critical to quantify the haematological impact attributable to *P. falciparum* infection and the clinical and demographic factors that underlie this. The aim of this study was to determine the pattern of haematological recovery following uncomplicated falciparum malaria and define the risk factors for moderately severe haematological outcomes at baseline and during early follow-up.

**Methods**

**The WWARN repository and study selection**

Haemoglobin concentrations are often not reported in antimalarial trial publications, even if these data are collected. Since a review of published literature would not provide sufficiently comprehensive information, the focus of this individual patient data meta-analysis was on studies identified in the WWARN repository. The WWARN repository contains data from 451 antimalarial efficacy studies in which patients were enrolled from locations in 69 countries, with a diverse range of *P. falciparum* transmission intensities. Data in the repository have been standardised and collated using methodology described previously in the WWARN Clinical Module Data Management and Statistical Analysis Plan [9].

The WWARN repository was searched in August 2015 for all antimalarial efficacy studies of uncomplicated *P. falciparum* malaria in non-pregnant patients that followed subjects prospectively for a minimum of 28 days and reported haemoglobin concentration (or haematocrit) at least at baseline (day 0). Investigators of the identified studies were invited to participate in this study group and information was made available on the WWARN website [10]. Uncomplicated *P. falciparum* malaria was defined as microscopy-proven falciparum malaria without features of severe malaria [11]. Patients were excluded if they had severe malaria.

**Outcomes of interest**

The primary outcome of the analysis was the risk of moderately severe anaemia (Hb < 7 g/dL) on day 7 after initiation of treatment. Secondary outcomes included the mean fall in haemoglobin at day of nadir and day 7, the timing of nadir haemoglobin, risk of moderately severe anaemia at days 0 and 3, and the risk of a large reduction in haemoglobin from baseline, defined as a fractional fall in Hb of ≥ 25% on day 3 or 7.

**Statistical methods**

All statistical analyses were done using R (Version 3.2.5, The R Foundation for Statistical Computing) or Stata MP 15, based on an a priori statistical plan shared with data contributors [10].

Haematocrit measurements were converted to haemoglobin concentrations using the following formula: Haemoglobin = (Haematocrit − 5.62)/2.60 [12]. The timing of sampling was defined as day 0 if occurring on the day of enrolment / first day of treatment, with sequential numbering thereafter. Data were stratified by region (Africa, Asia and South America). Univariable and multivariable mixed effects logistic regression models were used to model risk of (i) moderately severe anaemia on day 0, 3 or 7 and (ii) large reduction in haemoglobin on day 3 or 7. Study site (sites within countries) was included as a random intercept in these models.

Changes in mean haemoglobin over time were examined, after stratifying by region, using linear mixed effects models. Fractional polynomial terms for time were fitted as random effects for patients to capture the nonlinear associations and random intercepts for patients and study site. All available haemoglobin measurements were included in these analyses. Additional analyses of mean haemoglobin over time within each region were undertaken, stratified by age group (<5 years and ≥ 5 years).

For all regression models, independent risk factors were identified following the strategy recommended by Collet [13]. Covariates examined included the
following: age in years (categorised as < 1 year, 1 to 4 years, 5 to 11 years and ≥ 12 years), sex, fever (temperature > 37.5 °C) on enrolment, baseline parasitaemia (after log transformation), mixed Plasmodium species infection, underweight (defined as weight-for-age Z-score < −2 for children younger than 5 years) [14], high parasitaemia (defined as > 100,000 parasites/μL [15]), presence of gametocytaemia on enrolment, transmission intensity, treatment (artemisinin-based therapy versus non-artemisinin-based therapy) and parasite clearance (early clearance on day 1 or day 2 versus delayed parasite clearance on day 3 or later). Red cell indices were not available. Malaria transmission intensity was defined based on estimates of P. falciparum prevalence rate (PfPR) according to enrolment year and location [16], assuming low transmission for study sites with a PfPR < 0.15, moderate transmission if PfPR 0.15 to < 0.40 and high transmission if PfPR ≥ 0.40. Fractional polynomials were used to define the nonlinear relationships between outcome and continuous covariates.

Ethics
All data included in this analysis were obtained in accordance with ethical approvals from the countries of origin. The data are fully anonymised and cannot be traced back to individuals. This analysis did not require separate ethical approval according to the guidelines of the Oxford Central University Research Ethics Committee.

Results
A total of 200 P. falciparum clinical trials undertaken between 1991 and 2013 met the inclusion criteria and were available for analysis (Fig. 1, Additional file 1: Tables S1-S2, and Additional file 2: Figure S1) [1, 17–177]. Individual records were available from 70,226 patients, of whom 50,859 (72.4%) were enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America (Table 1). In Asia and South America, 61.8% (11,963/19,367) of the patients were male and 35.0% (6775/19,357) were younger than 12 years old. In African studies, there was an equal sex distribution (51.1% males, 25,566/49,998) and 88.3% (44,890/50,859) were younger than 12 years old. Overall, 76.5% (53,730) of patients received artemisinin-based treatment varying from 72.5% in Africa, to 87.2% in Asia and 89.6% in South America (Table 1 and Additional file 3: Table S3). In the 53,730 patients receiving an artemisinin-based treatment, artemether-lumefantrine (AL) was administered in 34.2% (18,359) of cases, artesunate-amodiaquine

![Fig. 1 Study flow diagram. Hb—haemoglobin; Pf—P. falciparum; Pv—P. vivax](image-url)
Table 1 Demographic and baseline characteristics

|                     | Africa N (%) or median (range) | Asia N (%) or median (range) | South America N (%) or median (range) |
|---------------------|-------------------------------|-------------------------------|--------------------------------------|
| Number of patients evaluated | 50,859                       | 18,451                       | 916                                  |
| Age (years)         | 3 (0.03–86.7)                 | 16 (0.2–88.0)                | 23 (3.1–65.0)                        |
| Age group           |                               |                               |                                       |
| < 1 year            | 4562 (9.0)                    | 67 (0.4)                     | 0 (0)                                |
| 1–4 years           | 31,225 (61.4)                 | 2071 (11.2)                  | 2 (0.2)                              |
| 5–11 years          | 9103 (17.9)                   | 4524 (24.5)                  | 111 (12.1)                           |
| ≥ 12 years          | 5969 (11.7)                   | 11,789 (63.9)                | 803 (87.7)                           |
| Sex                 |                               |                               |                                       |
| Female              | 24,432 (48.9)                 | 7054 (38.2)                  | 350 (38.2)                           |
| Male                | 25,566 (51.1)                 | 11,397 (61.8)                | 566 (61.8)                           |
| Haemoglobin (g/dL)^b| 9.9 (5.0–19.7)                | 11 (5.0–20.0)                | 12.3 (6.9–17.9)                      |
| Haematocrit (%)^c   | 31.6 (10.0–54.0)              | 36.3 (14.4–55.0)             | 37.3 (18–54.1)                       |
| Derived haemoglobin (g/dL)^d| 9.9 (5.0–19.7) | 11.6 (5.0–20.0) | 12.3 (6.9–17.9) |
| Anaemia             |                               |                               |                                       |
| Moderately severe anaemia (haemoglobin < 7 g/dL) | 4284 (8.4) | 605 (3.3) | 1 (0.1) |
| Moderate anaemia (haemoglobin 7–< 10 g/dL) | 21,676 (42.6) | 4260 (23.1) | 78 (8.5) |
| No anaemia (haemoglobin ≥ 10 g/dL) | 24,899 (49.0) | 13,585 (73.6) | 837 (91.4) |
| Temperature (°C)^e  | 38 (34.0–42.0)                | 37.7 (34.0–42.0)             | 37.5 (35.1–42.0)                     |
| Fever (temperature > 37.5 °C) | 32,266 (65.9) | 8937 (54.2) | 438 (48.0) |
| Parasitaemia (/μL) | 21,600 (2.5–486,080)          | 9375 (7–499,712)             | 4490 (8–149,925)                     |
| High parasitaemia (> 100,000/μl) | 5200 (10.2) | 1548 (8.4) | 3 (0.3) |
| Presence of gametocytaemia^f | 2339 (8.2) | 1530 (11.2) | 107 (11.8) |
| Underweight (WAZ < − 2)^g | 6205 (18.8) | 781 (39.0) | 2 (100) |
| Species of infection |                               |                               |                                       |
| Mixed P. falciparum and P. vivax | 0 (0) | 0 (0) | 0 (0) |
| P. falciparum mono-infection | 50,859 (100) | 17,300 (93.8) | 916 (100) |
| Transmission setting |                               |                               |                                       |
| High                | 19,766 (38.9)                 | 0 (0)                         | 0 (0)                                |
| Moderate            | 15,357 (30.2)                 | 561 (3.0)                     | 0 (0)                                |
| Low                 | 15,736 (30.9)                 | 17,890 (97.0)                | 916 (100)                            |
| Treatment           |                               |                               |                                       |
| Artemisinin-based   | 36,823 (72.5)                 | 16,086 (87.2)                | 821 (89.6)                           |
| Non-artemisin-based | 13,935 (27.5)                 | 2360 (12.8)                  | 95 (10.4)                            |

Total number of patients enrolled in Africa was 50,859, Asia was 18,451 and South America was 916

^a Data on patient sex were only available for 49,998 patients from Africa

^b Data on baseline haemoglobin were only available for 47,778 patients from Africa and 7139 patients from Asia

^c Data on baseline haematocrit were only available for 13,244 patients from Africa and 13,892 patients from Asia

^d The following conversion from haematocrit was used: haemoglobin = (haematocrit − 5.62)/2.60

^e Data on baseline temperature were only available for 48,982 patients from Africa and 16,483 patients from Asia

^f Data on baseline gametocytes were only available for 28,453 patients from Africa, 13,697 patients from Asia and 904 patients from South America

^g Data on weight-for-age Z-scores (WAZ) were only available for 33,048 patients from Africa, 2001 patients from Asia and 2 patients from South America. WAZ was only evaluated in children < 5 years

(ASAQ) in 19.6% (10,536), artesunate-mefloquine (ASMQ) in 14.5% (7764), dihydroartemisinin-piperaquine (DP) in 15.3% (8197), and other artemisinin-based treatments in 16.5% (8874) (Additional file 3: Table S3).

Haematological status at enrolment

The haematological exclusion criteria differed between studies. The commonest haematological exclusion criterion was a haemoglobin < 5 g/dL (used in 126 studies where 39,940 patients were included), with 2 studies (483
patients) excluding patients with a haemoglobin < 6 g/dL, 9 studies (5964 patients) excluding patients with a haemoglobin < 7 g/dL and 3 studies (566 patients) excluding patients with a haemoglobin < 8 g/dL. In 60 studies, haematological exclusion criteria were not stated; Additional file 1: Table S2. There were 208 patients with a haemoglobin < 5 g/dL at baseline, who were excluded from further analysis, since they met the WHO criteria for severe malaria.

The median haemoglobin at enrolment was 9.9 g/dL (range 5.0–19.7 g/dL) in Africa, 11.6 g/dL (range 5.0–20.0 g/dL) in Asia and 12.3 g/dL (range 6.9–17.9 g/dL) in South America (Table 1). Moderately severe anaemia was defined as haemoglobin concentration < 7 g/dL and was present in 4891 (6.9%) patients at baseline, with a prevalence of 8.4% (4284/50,859) in Africa, 3.3% (606/18,451) in Asia and 0.1% (1/916) in South America. Owing to the limited numbers of patients from South America, all subsequent analyses were restricted to patients from either Africa or Asia and stratified by geographical location.

The mean haemoglobin at enrolment varied with both age and baseline parasitaemia (Additional file 2: Figure S2). The main risk factors for moderately severe anaemia at baseline in both Africa and Asia were young age and presenting without high parasitaemia (> 100,000/μL); Additional file 3: Table S4 and S5. In Africa, the risk of moderately severe anaemia was inversely related to parasitaemia, whereas in Asia the risk rose to a peak at 10,000 parasites/μL, and decreased thereafter (Fig. 2).

**Haemoglobin profile following the start of treatment**

A linear mixed effects model of all haemoglobin concentrations over time showed that following the start of treatment haemoglobin concentration fell rapidly to a nadir on day 2 (Fig. 3). The estimated mean fall in haemoglobin in Africa was 0.57 g/dL at day 2 and 0.03 g/dL at day 7, with corresponding estimates in Asia of 1.13 g/dL and 0.78 g/dL. Haemoglobin concentrations returned to baseline by day 8 in Africa and day 22 in Asia, and thereafter continued to increase, reaching a mean concentration at day 42 of 11.40 g/dL (95%CI 11.28–11.52) in Africa (1.47 g/dL above baseline) and 12.17 g/dL (95%CI 11.98–12.36) in Asia (0.60 g/dL above baseline) (Fig. 3).

Haematological recovery was assumed to have occurred by day 42, and therefore, the observation on this day represented the baseline Hb of this patient population without infection. In African patients, 71.3% of the total fall in Hb from predicted baseline occurred before treatment and 28.3% after treatment. The corresponding percentages in Asia were 34.7% and 65.3% respectively. Differences in the haemoglobin profiles between Africa and Asia were largely attributable to the variation in the age distributions of the study populations. When
the analyses were stratified by age, the haemoglobin profiles were similar for the two continents (Fig. 3).

**Moderately severe anaemia after the start of treatment**

Overall, 9.1% (1129/12,460) of patients had moderately severe anaemia (Hb < 7 g/dl) on day 3 and 4.4% (1241/28,262) on day 7. The risk of falling below 7 g/dL in people who did not have moderately severe anaemia at baseline was greater in Africa than in Asia on both day 3 (9.6% (987/10,278) versus 6.5% (142/2,182); \( p = 0.001 \)) and day 7 (5.7% (987/17,198) versus 2.3% (254/11,064) respectively; \( p < 0.001 \)).

The following independent predictors of moderately severe anaemia at day 7 in both Africa and Asia were identified: moderately severe anaemia at baseline (AOR = 16.10 (95%CI 12.59–20.60), \( p < 0.001 \) for Africa and 23.00 (14.27–37.06), \( p < 0.001 \) for Asia), younger age (for age < 1 year compared to patients \( \geq 12 \) years AOR = 12.81 (95%CI 6.79–24.17), \( p < 0.001 \) for Africa and 23.00 (14.27–37.06), \( p < 0.001 \) for Asia), and parasitaemia > 100,000/μL (AOR = 1.78 (95%CI 1.42–2.24), \( p < 0.001 \) and 1.58 (1.10–2.27), \( p = 0.013 \)) (Table 2 and Additional file 3: Table S6, Fig. 4). In Africa, fever (AOR = 1.66 (95%CI 1.33–2.09); \( p < 0.001 \)) was an independent predictor of moderately severe anaemia whilst female sex (AOR = 0.80 (95%CI 0.69–0.93); \( p = 0.004 \)) was protective. In Asia, female sex was an independent predictor (AOR = 1.51 (95%CI 1.15–1.99), \( p = 0.003 \)) and mixed infection was protective (AOR = 0.44 (95%CI 0.24–0.80), \( p = 0.007 \)). The effect of sex was explored by evaluating the models separately in children compared with adolescents and adults. In adolescents and adults (age \( \geq 12 \) years), female sex was associated with moderately severe anaemia, and this reached statistical significance in Asia (AOR = 2.55 (95%CI 1.65–3.94), \( p < 0.001 \)), but not Africa (AOR = 1.98 (95%CI 0.71–5.49), \( p = 0.191 \)). In contrast, in children (age < 12 years) female sex was associated with a lower risk of moderately severe anaemia, reaching statistical significance in Africa (AOR = 0.78 (95%CI 0.67–0.91), \( p = 0.001 \)), but not Asia (AOR = 0.98 (95%CI 0.73–1.32), \( p = 0.903 \)).

Compared with those treated with non-artemisinin-based treatments, patients in Asia treated with artemisinin-based therapy were at significantly greater risk of moderately severe anaemia on day 7 (AOR = 2.06 (95%CI 1.39–3.05); \( p < 0.001 \)), but this was not the case in African patients (AOR = 1.01 (95%CI 0.56–1.82); \( p = 0.987 \)). In Asia, the difference in risk between artemisinin- and non-artemisinin-based treatments remained when only the 8570 patients enrolled before 2007 (when artemisinin resistance was first described in the Greater Mekong Sub-region) were included in the model (AOR = 1.98 (95%CI 1.56–2.52), \( p = 0.001 \)).

---

**Fig. 3** Relationship between haemoglobin and time from administration of first antimalarial dose for A all age groups, B patients < 5 years old and C patients \( \geq 5 \) years old. Figure derived from linear mixed effects model with fractional polynomial terms for time.
1.39–2.82); p < 0.001). Overall, the risk factors for moderately severe anaemia on day 3 were similar to those at day 7, with patients treated with artesminin-based therapy at significantly greater risk of moderately severe anaemia on day 3 in Asia (AOR = 3.27 (95% CI 2.42–4.42); p < 0.001), but not in Africa (AOR = 0.69 (95% CI 0.32–1.49); p = 0.343) (Additional file 3: Table S7-S8 and Additional file 2: Figure S3).

The fractional fall in haemoglobin on day 7 was correlated positively with the baseline haemoglobin (r = 0.47; p < 0.001 adjusted for clustering of study site). A high baseline haemoglobin was associated with a greater risk of a large fractional fall (≥ 25%) on day 7 in Africa (AOR for every 1 g/dL increase in baseline haemoglobin = 1.52 (95% CI 1.40–1.65); p < 0.001) and in Asia (AOR for every 1 g/dL increase in baseline haemoglobin = 1.43 (95% CI 1.35–1.52); p < 0.001) (Additional file 2: Figure S4). Other risk factors for a large fractional fall in haemoglobin on day 7 were similar to the risk factors for moderately severe anaemia on this day (Additional file 3: Table S9).

### Parasite clearance and moderately severe anaemia

Of the 13,939 African patients who had haemoglobin concentrations measured on day 7, 11.1% (1547) were parasitaemic on day 2 and 2.6% (358) were parasitaemic on day 3. The corresponding proportions in Asia were 14.9% (1339/8960) and 4.2% (375/8960). After controlling for confounding factors, the risk of moderately severe anaemia at day 7 was greater in patients with delayed parasite clearance in both Africa (AOR = 2.44 (95% CI 1.59–3.75); p < 0.001) and Asia (AOR = 2.59 (95% CI 1.20–5.58); p = 0.015) (Table 3). There was no interaction between artemisinin use and delayed parasite clearance.

### Assessment of potential bias

Methodological factors potentially contributing to bias are presented in Additional file 1: Table S2. Although many studies were unblinded, haemoglobin measurement is automated, thus minimising the risk of observer bias. Publication bias was unlikely, since haemoglobin concentration was measured on day 7 after completion of the study drug regimen.
Fig. 4 Relationship between predicted probabilities of moderately severe anaemia (haemoglobin < 7 g/dL) on day 7 and continuous covariates. Results come from the final multivariable models and are adjusted for mean values of other covariates (haemoglobin, age, parasitaemia, sex, fever, treatment (artemisinin-based vs non-artemisinin-based) and mixed infection (Asia only)). The model was restricted to children with age > 0.75 years and haemoglobin ≤ 17 g/dL due to instability at the extremes of the data.

Table 3 Effect of parasite clearance time on moderately severe anaemia after treatment

|                  | Africa |                        | Asia |                        |                  |
|------------------|--------|-------------------------|------|-------------------------|------------------|
|                  | % (Number with moderately severe anaemia/N<sup>a</sup>) | AOR (95% CI) | P value | % (Number with moderately severe anaemia/N<sup>a</sup>) | AOR (95% CI) | P value |
| **Moderately severe anaemia on day 3** |        |                        |      |                         |                  |
| Clearance between day 0 and day 1 | 6.5% (221/3410) | Reference |        | 4.4% (39/889) | Reference | |
| Clearance between day 1 and day 2 | 11.0% (473/4299) | 1.52 (1.20–1.92) | 0.001 | 6.5% (41/628) | 1.16 (0.57–2.36) | 0.685 |
| Clearance between day 2 and day 3 | 15.0% (94/626) | 2.26 (1.55–3.29) | < 0.001 | 6.3% (16/254) | 2.04 (0.76–5.47) | 0.156 |
| Clearance after day 3 | 11.5% (9/78) | 2.04 (0.82–5.09) | 0.126 | 2.5% (5/197) | 0.67 (0.06–7.08) | 0.742 |
| **Moderately severe anaemia on day 7** |        |                        |      |                         |                  |
| Clearance between day 0 and day 1 | 4.8% (243/5106) | Reference |        | 1.6% (52/3177) | Reference | |
| Clearance between day 1 and day 2 | 6.1% (417/6834) | 1.02 (0.76–1.35) | 0.916 | 2.7% (100/3759) | 1.32 (0.87–2.01) | 0.187 |
| Clearance between day 2 and day 3 | 8.4% (99/1182) | 1.28 (0.88–1.85) | 0.199 | 2.8% (26/938) | 1.57 (0.92–2.68) | 0.102 |
| Clearance after day 3 | 12.4% (44/354) | 2.44 (1.59–3.75) | < 0.001 | 2.9% (10/346) | 2.59 (1.20–5.58) | 0.015 |

Effects are adjusted for all independent predictors identified in the final multivariable models for Africa and Asia in Table 2 (Main text) and Additional file 3: Table S8. AOR adjusted odds ratio. *N number of patients for each variable/levels of factors.
measurements were not a primary outcome in any of the publications and haemoglobin concentrations are unlikely to have influenced the decision to publish. Exclusion due to variable haemoglobin criteria will have caused a small reduction in the apparent proportion of patients with moderately severe anaemia at baseline and may also have artificially reduced the proportion of patients becoming severely anaemic during follow-up. In a sensitivity analysis, exclusion of patients from the 14 studies that had baseline haemoglobin cut-offs greater than 5 g/dL had minimal impact on the results (Additional file 3: Tables S10 and S11).

Discussion
Our study provides a detailed analysis of haemoglobin concentration kinetics in patients with falciparum malaria, enrolled across geographically diverse regions. The available data, exceeding > 70,000 individual data from patients of all ages, provides unprecedented power to define the factors associated with the acute fall in haemoglobin before and after treatment. Malaria is due to an intraerythrocytic infection which results in a reduction of red blood cells, intra- and extravascular haemolysis, bone marrow suppression and sequestration [178]. The administration of antimalarial drugs inhibits these pathological processes by preventing parasite replication and limiting the duration of dyserythropoiesis. Hence, the haematological manifestations of malaria are a function of the duration and degree of parasitaemia prior to treatment and the speed of therapeutic response to antimalarial treatment. Our analysis demonstrated that in Africa, hence in generally relatively high transmission regions, approximately three quarters of the malaria-attributable fall in haemoglobin occurs before presentation and one quarter after treatment, whilst in Asia, in generally relatively low transmission settings, one third occurs before presentation and two-thirds after treatment. The relative drop in haemoglobin was positively correlated with baseline haemoglobin.

Although the greatest fall in haemoglobin occurred before treatment in Africa, our analysis focused primarily on factors associated with the subsequent fall and recovery which may be more amenable to clinical intervention. Consistent with a recent pooled analysis from Africa [179], our study found that in both Africa and Asia, the nadir haemoglobin occurred within 2 days of starting treatment and haemoglobin generally rose thereafter. Whilst a previous analysis identified that nadir haemoglobin occurred on day 7, this was based on weekly assessments, and thus would have missed the true nadir occurring between weekly observations [1]. In vulnerable populations, such as young children and pregnant women, who are at risk of adverse clinical outcomes, antimalarial clinical trials should implement a routine haemoglobin assessment at day 2 or 3 to ensure early diagnosis of severe anaemia.

The baseline haemoglobin in patients with falciparum malaria varied substantially with age and parasite density at presentation. After controlling for confounding factors, significant site to site variation remained, likely reflecting variations in transmission intensity, host immunity and factors unrelated to malaria. Patients from Asia tended to be older than those enrolled in Africa, but after controlling for age there were minimal differences in haemoglobin between regions, either at baseline or during follow-up. Following treatment, the absolute and proportional reductions in haemoglobin were greater in patients from Asia compared to Africa and were correlated with the higher baseline haemoglobin in Asian patients. Hence, patients presenting with a low haemoglobin concentration were less likely to experience a further fall in their haemoglobin.

The relationship between level of parasitaemia and degree of anaemia is complex [1, 179]. In Africa, anaemia at presentation was greatest in patients with low parasitaemias. There are several possible explanations for this. First, in highly endemic parts of Africa, robust immunity develops early, suppressing parasitaemia and symptoms. A substantial proportion of patients presenting with fever and low-level Plasmodium parasitaemia in these regions will have an alternative diagnosis, such as bacterial sepsis, which is also associated with anaemia [180]. Second, immune-mediated suppression of malaria symptoms can result in chronic, untreated parasitaemia that, over time, leads to significant suppression and dysregulation of haematopoiesis. Third, repeated episodes of malaria can result in splenic sequestration, with low-level peripheral parasitaemia, associated splenomegaly and dilutional anaemia [178, 181].

In Asia, the risk of anaemia at presentation increased with rising parasitaemia, peaking at 10,000 parasites/μL before decreasing thereafter. As transmission intensity in endemic parts of Asia is generally significantly lower than in Africa, immunity is less robust and a much greater proportion of infections will be symptomatic and of short duration. In this setting, anaemia will be related primarily to acute destruction of both parasitised and unparasitised red cells, the severity of which is correlated with the level of parasitaemia.

Treatment with artemisinin-based therapy in Asia was associated with a twofold higher risk of moderately severe anaemia (but not a large fractional fall in haemoglobin) within 7 days compared with non-artemisinin-based therapy, whereas in Africa, artemisinin-based treatment was not associated with an excess risk of early anaemia. This
relationship was not attributable to the presence of artemisinin resistance. We hypothesise that rapid killing of intraerythrocytic parasites by artemisinins in non-immune Asian adults likely leads to more rapid clearance of whole red blood cells from the circulation than that occurring after slower acting drug treatments. In immune African patients, a greater proportion of infected red cells undergo targeted intraerythrocytic parasite removal (pitting) followed by a return to circulation, thus ameliorating the early development of anaemia [6]. Reticulocytosis probably also occurs more rapidly after treatment in immune compared with non-immune individuals [6]. Further studies are warranted to explore the differences in haematological response to treatment with artemisinin derivatives in populations with different levels of immunity. Our analysis is based upon studies conducted prior to 2014. In the last 5 years, artemisinin-resistant parasites have spread across the Greater Mekong Subregion [182], with recent reports confirming their presence in Sub-Saharan Africa [183, 184]. Slower parasite clearance times and subsequent emergence of resistance to partner drugs will ultimately lead to treatment failure that will impact the generally prompt haemoglobin recovery that we observed in our analysis.

Our study has a number of limitations. The analysis focused on the acute haematological impact of malaria and the early recovery phase and did not address the influence of late treatment failure on subsequent recovery to baseline haemoglobin concentrations. This will be addressed in a subsequent analysis. Our estimates of the pattern of haemoglobin changes during the first few days after diagnosis may have been influenced by selection bias, as only a small subset of patients had multiple haemoglobin measurements during the first 7 days of follow-up. Although we did not employ a traditional systematic review to identify eligible studies, our analysis is the largest meta-analysis to date of patients treated for malaria in both Africa and Asia. This unprecedented data collection ensures robust parameter estimates and minimises the risk of inclusion bias. Furthermore, a systematic review would not preclude bias, since some studies recorded haemoglobin/haematocrit measurements but did not present these data in published manuscripts. Whilst the results of the current study are likely to be generalisable to Africa and Asia, the small number of patients from the Americas prevents the generalisability of our findings to this region. An additional potential cause of bias is the exclusion of patients from the original studies, prior to pooling, according to variable definitions of severe anaemia. Almost two-thirds of studies excluded patients with a haemoglobin < 5 g/dL, with a few studies excluding patients based on higher cut-offs and the remaining 30% having an unknown cut-off. Additional limitations of our study include the use of various methodologies to measure haematocrit or haemoglobin, a lack of a robust conversion factor to adjust haematocrit to haemoglobin in different studies’ populations and no reliable data on the following confounding factors that can influence haemoglobin and its recovery: the duration of prior parasitaemia (which has been shown to correlate with anaemia at presentation [178]), host genetic factors associated with anaemia (e.g. sickle cell anaemia, thalassaemia), administration of haematinics (or treatment for anaemia) and hydration status.

Conclusions

In conclusion, the majority of patients with uncomplicated falciparum malaria had a modest fall in haemoglobin following treatment, before subsequent improvement in haemoglobin during recovery. Despite highly effective treatment, some patients remained at significant risk of moderately severe anaemia. Young children had a particularly high risk, likely related to lower immunity and high initial peripheral parasitaemia. The risk of anaemia is exacerbated by prolonged parasitaemia prior to presentation [1] or delayed parasite clearance, both of which are associated with suboptimal treatment regimens particularly in areas where antimalarial drug resistance was emerging [185]. Whilst artemisinin-based treatment generally ensured rapid parasite clearance and high efficacy, in Asia their use was associated with a greater risk of moderately severe anaemia on day 3 and day 7 that could not be accounted for by an underlying rise in artemisinin resistance. Early diagnosis of malaria and treatment with highly effective antimalarials remains critical in minimising anaemia associated with P. falciparum infection.

Abbreviations

ACT: Artemisinin-based combination therapy; AL: Artemether-lumefantrine; AOR: Adjusted odds ratio; ASAQ: Artemether-amodiaquine; ASMQ: Artesunate-mefloquine; CI: Confidence interval; DP: Dihydroartemisinin-piperaquine; PPR: P. falciparum parasite rate; WAZ: Weight-for-age Z-score; WHO: World Health Organization.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02265-9.

Additional file 1: Table S1. Describes studies included in the analysis. Table S2. Describes assessment of bias by included study. Additional file 2: Figure S1. Describes study sites. Figure S2. Describes the relationship between haemoglobin on enrolment and continuous covariates. Figure S3. Describes the relationship between the predicted probability of moderately severe anaemia on day 3 and continuous covariates. Figure S4. Describes the relationship between the predicted probability of a large fractional fall in haemoglobin on day 7 and continuous covariates. Additional file 3: Table S3. Describes the overview of antimalarial treatments. Table S4. Describes the risk factors for moderately severe anaemia at enrolment (univariable logistic regression). Table S5. Describes the risk
factors for moderately severe anaemia at enrolment (multivariable logistic regression). Table S5. Describes the risk factors for moderately severe anaemia at day 7 (multivariable logistic regression). Table S6. Describes the risk factors for moderately severe anaemia at day 7 (univariable logistic regression). Table S7. Describes the risk factors for moderately severe anaemia at day 3 (univariable logistic regression). Table S8. Describes the risk factors for moderately severe anaemia at day 3 (multivariable logistic regression). Table S9. Describes the risk factors for a large fractional fall in haemoglobin by day 7. Table S10. Describes the sensitivity analysis for risk factors for moderately severe anaemia at enrolment (multivariable logistic regression). Table S11. Describes the sensitivity analysis for risk factors for moderately severe anaemia at day 7 (multivariable logistic regression).

Acknowledgements

We thank all patients and staff who participated in these clinical trials at all the sites and the WWARN team for technical and administrative support. We specifically acknowledge the following investigators: Gabriel Carrasquilla, Francesco Checchi, Ogebara K Doumbo, Oumar Faye, Babacar Faye, Daddi Jima, Joel Jones, Moussa Koné, EléFath Malik, Achille Massougbodji, Clara Menéndez, Carolyn Nasabumuka, Ngoinga Ndounga, Christian Nsanazabana, Olivier Prat, Usula Sag威, Young Se, Colín J Sutherland, Khadime Sylla, Roger CK Tine. Material has been reviewed by the Walter Reed Army Institute of Research and the Centers for Disease Control and Prevention. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense or the Centers for Disease Control and Prevention. The investigators have adhered to the policies for protection of human subjects as prescribed in AR 70-25.

The members of the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group are the authors of this paper: Rashid Manosroi (WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK; Department of Statistical Science, University College London, London, UK), Robert J Commons (WorldWide Antimalarial Resistance Network (WWARN), Darwin, Australia; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; Internal Medical Services, Ballarat Health Services, Ballarat, Victoria, Australia), Nicholas M Douglas (Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia), Benjamin Abukou (Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana), Jane Achan (Uganda Malaria Surveillance Project, Kampala, Uganda, Malaraa Consortium, UK), Ishag Adam (Faculty of Medicine, University of Khartoum, Khartoum, Sudan), George O Adeji (Centre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, Accra, Ghana), Martin Adjuik (Navrongo Health Research Centre, Navrongo, Ghana, INDEPTH NETWORK Secretariat, Accra, Ghana), Bereket K Abebe (Malian School of Public Health, University of Pennsylvania, New York, NY, USA), Richard Allan (The MENTOR Initiative, Burns House, Harlands Road, Haywards Heath, West Sussex, UK), Elizabeth N Allen (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; WorldWide Antimalarial Resistance Network (WWARN), University of Cape Town, Cape Town, South Africa), Anupkumar R Arvik (National Institute of Malaria Research, New Delhi, India), Emmanuel Aritawite (Makerere University-University of California San Francisco Research Collaboration, University of California, San Francisco, USA), Infectious Diseases Research Collaboration, Kampala, Uganda), Elizabeth A Ashley (Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Mae Sot, Thailand; Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand), Hazel Ashurst (WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK), Puji BS Asik (Eijkman Institute for Molecular Biology, Jakarta, Indonesia), Nathan Bakyaita (Ministry of Health, Kampala, Uganda, World Health Organization, Zamb), Hubert Barennes (Agence Nationale de Recherche sur le Sida (ANRS), Paris, France; Unité d’Epidémiologie d’Intervention Centre Muraz, Bobo Dioulasso, Burkina Faso; Institut Francais pour la Médecine Tropicale, Ventiane, Laos), Karen I Barnes (Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; WorldWide Antimalarial Resistance Network (WWARN), University of Cape Town, Cape Town, South Africa), Leonardo Basco (Institut de Recherche pour le Développement (IRD), UMR 198, Marseille, France; Laboratoire de Recherche sur le Paludisme, Organisation de Coordination pour la lutte contre les Épidémies en Afrique Centrale (OCEAC), Yaoundé, Cameroon); Quique Bassat (Centro de Investigación en Salud de Manchíca (CISMI), Maputo, Mozambique; ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain; ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain), Elisabeth Baudin (Epicentre, Paris, France), David J Bell (Infectious Diseases Unit, Queen Elizabeth University Hospital, Glasgow, United Kingdom), Delia Bethell (US Army Medical Component-Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), Bangkok, Thailand), Anders Bjorkman (Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK; The Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand), Robert J Commons (WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; The Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand), Michael Cot (Institut de Recherche pour le Développement (IRD), Mother and Child Health in the Tropics Research Unit, Cotonou, Benin, Université de Paris, Paris, France), Umberto D’Alessandro (MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia), Debashish Das (Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand), Sabyasachi Das (Department of Physiology, Faculty of Medicine, Manipal University College Malaysia, Bukit Baru, Melaka, Malaysia), Timothy ME Davis (Medical School, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia), Meghna Desai (CDC Division of Parasitic Diseases and Malaria, CDC Atlanta, GA, USA; Kenya Medical Research Institute, Nairobi, Kenya), Abdoulaye A Djimde (Malaria Research and Training Center, Faculty of Pharmacy, University of Science, Technologies and Universities of Bamako, Bamako, Mali), Arjen M Donkor (Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK), Grant Dorsey (Department of Medicine, University of California San Francisco, San Francisco, CA, USA), Chris J Drakeley (Department of Infection Biology, London School of Tropical Medicine and Hygiene, United Kingdom), Stephan Duparc (Medicine for Malaria Venture, Geneva, Switzerland), Emmanuelle Espié (Epicentre, Paris, France; GSK Vaccines, Rixensart, Belgium), Jean-Francois Etaud (Epicentre, Paris, France; TransVHI (Institut de Recherche pour le Développement, IRD UMI 233), Institut National de la Santé et de la Recherche Médicale, INSERM U 1175, Université de Montpellier); Montpellier, France), Catherine Falade (Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria), Jean Franco Faucher (Institut de Recherche pour le Développement (IRD), Mother and Child Health in the Tropics Research Unit, Cotonou, Benin; Tropical Neuroepidemiology, INSERM UMR 1094, Limoges, France; Infectious diseases and tropical medicine department, Limoges University Hospital, Limoges, France), Scott Filler (The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland), Caroline Fogé (Epicentre, Paris, France; School of Health Sciences, University of Southampton, UK), Mark Fukuda (US Army Directorate Armed Forces Research Institute of Medical Sciences – AFRIMS, Bangkok, Thailand), Oumar Gaye (Department of Medical Parasitology, Medical Faculty, Université Cheikh Anta Diop, Dakar, Senegal), Blaise Genton (Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland), Awad Chuhlum Rahim (Medical Faculty, Nangarhar University, Jalalabad, Afghanistan; MORU Tropical Health Network, Bangkok, Thailand), Julius Gilayenh (National Malaria Control Program, Ministry of Health, Republic of Liberia), Raquel González (Centro de Investigación en Saúde de Manchíca, Manchíca, Mozambique; ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain), Rebecca F Grais (Epicentre, Paris, France), Francesco Grandesso (Epicentre, Paris, France), Brian Greenwood (Department of Diseases Control, London School of Hygiene and Tropical Medicine, London, London, UK), Philippe Brasseur (Institut de Recherche pour le Développement (IRD), Dakar, Sénégal), Hasifa Bukirwa (Uganda Malaraa Surveillance Project, Kampala, Uganda), Rebekah Burrow (WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK), Verena I Carrara (Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; The Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand), Michel Lacoste (Institut de Recherche pour le Développement (IRD), Mother and Child Health in the Tropics Research Unit, Cotonou, Benin, Université de Paris, Paris, France), Umberto D’Alessandro (MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia).
Author's contributions
RM1, RJC, NMD, JAS, PJG, KS and RNP conceived the idea and wrote the first draft of the manuscript. HA, RB and GSH curated the data. RM1, KS, RJC and JAS undertook the analysis. PJG, KS and RNP acquired the funding. RB, GSH and CLR managed and coordinated the study. BA, JA, IA, GOA, MA, BHA, RA, ENA, AA, EA, EAA, PBSA, NB, HB1, KIB, LB, QB, EB, DJB, DB, AB, CB, TB, PB, HB2, VC, MC, UDA, DD, SD1, TMD, MD, AAD, AMD, MD, GO, CJD, SD2, EE, JE, JFE, CF1, JFF, SF, CF2, MF, MG, OGM, CG, AGR, LG, RG, RFG, FG, BG2, AG, CH, EMH, JH, DSL1, EJ, SPK, PK1, EK, MRK, CK, KK1, AK, JRK, PK2, PK2, PKG, DGL, ML, SIL, BL, AW, AM, AMM, WM, RM2, HM, DM, FM, BRM, OMM, AM, JLN, PNN, BBN, FF1, AMN, HN, FN2, BRO, KO, LO, JBO, SOA, AP, LKP, PP, MP, ZP, MR, LR, CR, PJR, SS, ASE, LVS, CS, SBS, FS, FAS, SGS, PS, NSW, IS, TDS, DS, AOT, WRT, EAT, JHT, HT, ET, OAT, THU, JU, IV, GV, MVV, SAW, VW, VN, CW, WJ, WY, AY and IZ collected the data. RM1, RJC, NMD, JAS, PJG, KS and RNP interpreted the data and contributed to writing the first draft of the manuscript. BA, JA, IA, GOA, MA, BHA, RA, ENA, AA, EA, EAA, PBSA, NB, HB1, KIB, LB, QB, EB, DJB, DB, AB, CB, TB, PB, HB2, VC, MC, UDA, DD, SD1, TMD, MD, AAD, AMD, GO, CJD, EE, JE, JFE, CF1, JFF, SF, CF2, MF, MG, OGM, CG, AGR, LG, RG, RFG, FG, BG2, AG, CH, EMH, JH, DSL1, EJ, SPK, PK1, EK, MRK, CK, KK1, AK, JRK, PK2, PK2, PKG, DGL, ML, SIL, BL, AW, AM, AMM, WM, RM2, HM, DM, FM, BRM, OMM, AM, JLN, PNN, BBN, FF1, AMN, HN, FN2, BRO, KO, LO, JBO, SOA, AP, LKP, PP, MP, ZP, MR, LR, CR, PJR, SS, ASE, LVS, CS, SBS, FS, FAS, SGS, PS, NSW, IS, TDS, DS, AOT, WRT, EAT, JHT, HT, ET, OAT, THU, JU, IV, GV, MVV, SAW, VW, VN, CW, WJ, WY, AY and IZ collected the data.

Funding
RJC is funded by an Australian National Health and Medical Research Council (NHMRC) Emerging Leader Investigator Grant (11149702). RNP is a Wellcome Trust Senior Fellow in Clinical Science (2009009). JAS is funded by an Australian NHMRC Senior Research Fellowship 1104975. NWJ is a Wellcome Trust Principal Fellow. WWARN is funded by Bill and Melinda Gates Foundation and Exxon Mobil Foundation grants. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the paper. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
9. WorldWide Antimalarial Resistance Network (WWARN). WWARN Clinical Module: Data Management and Statistical Analysis Plan Version 1.2. WWARN. 2012.

10. A pooled analysis of haematological recovery after treatment with an ACT for Plasmodium falciparum Version 17.07.14 [http://www.wwarn.org/working-together/study-groups/haematology-study-group]

11. World Health Organization. Guideline for the treatment of malaria. 3rd ed. World Health Organization. Geneva, 2015.

12. Lee SJ, Stepniewska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the haemoglobin concentration and the haema-
tocrit in Plasmodium falciparum malaria. Malar J. 2008;7(1):19.

13. Collett D. Modelling survival data in medical research. Chapman and Hall/CRC. New York, 2015.

14. World Health Organization. WHO child growth standards: length/height for age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age, methods and development: World Health Organi-
ization. 2006.

15. World Health Organization. Severe Malaria. Tropical Med Int Health. 2014;19:7–131.

16. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the global prevalence, incidence, and mortality of Plasmo-
dium falciparum, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):322–31.

17. Luxemburger C, Nosten F, Raymond SD, Chongsuphasajiddhi T, White NJ. Oral artesunate in the treatment of uncomplicated hyperpara-
sitemic falciparum malaria. Am J Trop Med Hyg. 1995;53(5):525–4.

18. Bouyoy-Akotet MK, Ramharter M, Ngoungou EB, Mamfoumbi MM, Mihindou MP, Missinou MA, et al. Efficacy and safety of a new pedi-
atric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr. 2010;122(5–6):173–8.

19. Menan H, Faye O, Same-Ekobo A, Oga AS, Faye B, Kiki Barro CP, et al. Comparative study of the efficacy and tolerability of dihydroarte-
simin-pipaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar J. 2011;10:185.

20. Depoortere E, Guthmann JP, Pesse J, Siplanyambe N, Nkandu E, Balkan S, et al. Efficacy and effectiveness of the combination of sulfadoxine/ pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Tropical Med Int Health. 2005;10(2):139–45.

21. Checchi F, Reddy P, Kamara S, Williams A, Morineau G, Wurie AR, et al. Antimalarial efficacy of chloroquine, amodiaquine, artesunate and sulfadoxine-pyrimethamine: a comparison in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg. 2005;99(7):485–92.

22. Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012;11:355.

23. Starzingeruger P, Swoboda F, Fuehner HP, Khan WA, Hofecker V, Siedl A, et al. Current status of artesinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in Bangla-
desh. PLoS One. 2012;7(2):e25236.

24. Svarnhout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C. Artesunate + amodiaquine and artesunate + sulfadoxine-
pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulfadoxine and pyrimethamine-resistant haplotypes. Tropical Med Int Health. 2006;11(10):1053–11.

25. Valea I, Tinto H, Tracei-Coulibay M, Toe LC, Lindegardh N, Tarning J, et al. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmo-
dium falciparum infection in Burkina Faso. J Antimicrob Chemother. 2014;69(9):2499–507.

26. Kayentao K, Maiga H, Newman RD, Morrow ML, Hoppe A, Yattara O, et al. Artemisinin-based combinations versus amodiaquine plus sulphasodine-pyrimethamine for the treatment of uncomplicated malaria in Falaje, Mali. Malar J. 2009;8:5.

27. Menard D, Ratsimbason A, Randrianarivelosoa M, Rabarieraopa LP, Raha-
rimala L, Damarle O, et al. Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials. Malar J. 2008;7:55.

28. Tine RC, Faye B, Sylia K, Ndiaye JL, Ndiaye M, Sow D, et al. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treat-
ment of uncomplicated malaria in adult in Senegal: open randomized clinical trial. Malar J. 2012;11:416.

29. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaiupin L, Chong-
suphasajiddhi T, et al. Artesunate/mefloquine treatment of multi-
drug resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91(5):574–7.

30. Jullien V, Valecha N, Sirivastava B, Sharma B, Kiechel JR. Population pharmacokinetics of mefloquine, administered as a fixed-dose combi-
nation of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:187.

31. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised versus unsupervised intake of six-dose artemether-
lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005;365(9469):1467–73.

32. Smithuis F, Jayaw MK, Phe O, Win T, Aung PP, Oo AP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10(10):673–81.

33. Price RN, Nosten F, Luxemburger C, Kham A, Brockman A, Chong-
suphasajiddhi T, et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1995;89(5):523–7.

34. Tekete MM, Toure S, Fredericks A, Beavogui AH, Sangare CP, Evans A, et al. Effects of amodiaquine and artesunate on sulfadoxine-
pyrimethamine pharmacokinetic parameters in children under five in Mali. Malar J. 2011;10:275.

35. Falade C, Makanja M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncompli-
cated falciparum malaria. Trans R Soc Trop Med Hyg. 2005;99(6):549–67.

36. Anninwet E, Sandison TG, Warziza H, Kakuru A, Hommy J, Kalanya J, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children under five in Papua New Guinean children with uncomplicated malaria. Trans R Soc Trop Med Hyg. 2012;106(10):2110–9.

37. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91(3):497–505.

38. Moore BR, Benjamin JM, Saliman S, Griffin S, Ginny E, Page-Sharp M, et al. Effect of coadministered fat on the tolerability, safety, and phar-
macokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58(10):5784–94.

39. Zongo I, Dorsey G, Rouamba N, Tinto H, Domokialaj C, Guiguemde RT, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal randomized trial in young Ugandan children. Clin Infect Dis. 2009;49(11):1629–37.

40. Dorsey G, STAEDKE SK, CLARK TD, NJAMA-MEYA D, Nzarubara B, Maiteki-
Sebuguzi C, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007;297(20):2210–9.

41. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Artemisinin-based combinations versus amodiaquine plus sulphasodine-pyrimethamine for the treatment of uncomplicated malaria in Falaje, Mali. Malar J. 2009;8:5.
treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J. 2010;9:105.

45. Stivanello E, Cavalleri P, Cassano F, Omar SA, Kariuki D, Mwangi J, et al. Efficacy of chloroquine, sulphadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in Kaji Keji county, Sudan. Tropical Med Int Health. 2004;9(9):975–80.

46. Karem C, Fanello CI, van Overmeir C, van Geertruyden JP, van Dorenb W, Ngamje D, et al. Safety and efficacy of dihydroartemisinin-piperazine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006;100(12):1105–11.

47. Abdulla S, Sagara I, Bormann S, D’Alessandro U, Gonzalez R, Hamel M, et al. Efficacy and safety of artether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet. 2008;372(9652):1819–27.

48. Vugt MV, Waliatapa P, Gemperti B, Gathmann J, Phiapun L, Brockman A, et al. Efficacy of six doses of artether-lumefantrine (benfluemeth) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999;60(6):936–42.

49. Sylla K, Abiola A, Tine RC, Faye B, Sow D, Ndiaye JL, et al. Monitoring the efficacy and safety of three artesinin-based combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis. 2015;15:398.

50. Allen EN, Little F, Camba T, Cassam Y, Raman J, Boulle A, et al. Efficacy of chloroquine, sulphadoxine-pyrimethamine and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Malar J. 2009;8:141.

51. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis. 2002;35(12):1498–504.

52. Ashley EA, Krudsood S, Phiapun L, Srivilairit S, McGready R, Leowat M, et al. Efficacy of artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J Infect Dis. 2015;211(5):869–77.

53. Lee SJ, Onyango P, Otieno K, Odero C, Williamson J, Grande T, et al. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine combination for the treatment of uncomplicated malaria in children under 5 years in Kilainah, Sierra Leone. Tropical Med Int Health. 2006;11(7):1017–21.

54. Kamugisha E, Jing S, Minde M, Katafahy J, Kongola G, Kirondo F, et al. Efficacy of artesunate-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malar J. 2012;11:58.

55. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Eh JP, Chongsuphasiddhi T, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 1994;170(4):971–7.

56. Faye B, Kueti T, Kiki Barro CP, Tine RC, Nkia T, Ndiaye JL, et al. Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J. 2012;11:433.

57. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Snawbridge S, et al. Efficacy of high-dose or low-dose artesunate in parasite clearance in artesinin-resistant falciparum malaria. Clin Infect Dis. 2013;56(5):e48–58.

58. Schirrmh B, Valle S, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Tolerability and safety of artesunate-amodiaquine and artether-lumefantrine in children with uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Niamba County, Liberia. Malar J. 2013;12:250.

59. Agarwal A, McMorris M, Onyango P, Onisto K, Odero C, Williamson J, et al. A randomized trial of artether-lumefantrine and dihydroartesinin-piperazine in the treatment of uncomplicated malaria among children in western Kenya. Malar J. 2013;12:254.

60. Grande T,Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, et al. A randomised controlled trial to assess the efficacy of dihydroartesinin-piperazine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One. 2007;2(10):e1101.

61. Adjoue A, Gnampey P, Babiker A, Bormann S, Brasseur R, Cisse M, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002;359(9315):1365–72.
for the treatment of uncomplicated falciparum malaria in Kampa,
Uganda. Am J Trop Med Hyg. 2003;68(2):127–32.

79. Ngasala BE, Malmberg M,Carlsson AM,Feerre PE,Petzold MG,Bless-
born D, et al. Efficacy and effectiveness of artemether-lumefantrine
after initial and repeated treatment in children <5 years of age with
acute uncomplicated Plasmodium falciparum malaria in rural Tanzania:
a randomized trial. Clin Infect Dis. 2011;52(7):873–82.

80. Carrasquilla G,Baron C, Monsell EM, Couzin M, Walter V, Lefevre G, et al.
Randomized, prospective, three-arm study to confirm the auditory
safety and efficacy of artemether-lumefantrine in Colombian patients
with uncomplicated Plasmodium falciparum malaria. Am J Trop Med
Hyg. 2012;86(1):75–83.

81. Mayxay M,Kanthavong M, Lindegardh N, Keola S, Barends M,
Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM,
Luxemburger C, ter Kuile FO, Nosten F, Dolan G, Bradol JH, Phaipun L,
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M,
Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al.
Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA,
Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al.
Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, et al.
Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR,
Checchi F, Piola P, Kosack C, Ardizzoni E, Klarkowski D, Kwezi E, et al.
Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA,
et al. Efficacy and safety of artemether-lumefantrine and dihydroarte-
missin-piperazine in the treatment of uncomplicated Plasmodium falciparum malaria in children less than five years of age.
Am J Trop Med Hyg. 2004;70(2):173–40.

85. Sirima SB, Tiono AR, Kariuki J, Ouma J, Odero CO, Oduhambo FO, Otieno KO, Kariuki S, Ord R, et al. In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Tropical Med Int Health. 2004;9(1):8–16.

90. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR, Dorsey G, et al. Effectiveness of quinine versus artesunate-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: a randomised controlled trial. BMJ. 2009;339:b2763.

95. Price R, Luxemburger C, van Vught M, Nosten F, Kham A, Simpson J, et al. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92(2):207–11.

100. Bell DJ, Wootton D, Mwawuka M, Montgomery J, Kayange N, Chimpeni P, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8:204.
111. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Ann Trop Paediatr. 1996;16(4):281–6.

112. van den Broek I, Arnsau R, Balasaegaram M, Hepple P, Alemu E, Hussein el B, et al. Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malar J. 2005:4;14.

113. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, et al. A randomized trial of artesunate-mefloquine versus artesether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2008;79(5):655–61.

114. Barnes KE, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80(6):582–96.

115. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, Barnes KI. Malaria prevalence in Africa: lessons from a pilot project in Mambanga Province. South Africa Drug Saf. 2007;30(10):999–910.

116. Rwigacundo GE, Karena C, Mugisha V, Erfhart A, Dujardin JC, Van Overmeir C, et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Tropical Med Int Health. 2004;9(10):1091–8.

117. Checchi F, Balkan S, Vonh BT, Matassiqo MB, Biberon P. Eldin de Pecoulas P, Bresseur P, Guthmann JP. Efficacy of amodiaquine for uncomplicated Plasmodium falciparum malaria in Harper, Liberia. Trans R Soc Trop Med Hyg. 2002;96(6):670–3.

118. Nji AM, Ali IM, Moyeh MN, Ngongang E, Ekollo AM, Chediou JP, et al. Randomized non-inferiority and safety trial of dihydroartemisinin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar J. 2015;14:27.

119. Abakua B, Duah N, Quaye L, Quashie N, Koram K. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J. 2012;11:388.

120. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993;341(8852):1044–9.

121. Staedke SG, Mpimbaiza A, Kamya MR, Nzurubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Uganda: randomised clinical trial. Lancet. 2004;364(9449):1590–7.

122. Ogotu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, et al. Fixed dose artesunate-amodiaquine—a phase IIIb, randomised comparative trial with non-fixed artesunate-amodiaquine. Malar J. 2014;13:498.

123. Toure OA, Assi SB, Nguesse SL, Adjé GE, Ako AB, Brou M, et al. Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Cote d’Ivoire. Malar J. 2014;13:439.

124. van den Broek I, Kitz C, Al Attas S, Libuma F, Balasaegaram M, Guthmann JP. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J. 2006;5:113.

125. Sirima SB, Tiono AB, Konate A, Diarra A, Castelli F, Pinoges L, et al. Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: a double-blind, randomized, controlled trial. Trans R Soc Trop Med Hyg. 2003;97(3):345–9.

126. Fogg C, Twiessyge R, Batwala V, Piola P, Nabasumba C, Kiguli J, et al. Assessment of three new parasite lactate dehydrogenase (pan-pLDH) tests for diagnosis of uncomplicated malaria. Trans R Soc Trop Med Hyg. 2008;102(1):25–31.

127. Juma EA, Obonyo CO, Akhwaile WS, Ogotu BR. A randomized, open-label, comparative efficacy trial of artesunate-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar J. 2008;7:262.

128. Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, et al. A randomized trial of artesunate-sulfadoxine-pyrimethamine versus artesether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2006;75(4):630–6.
artemisinin combination therapies in Davola and molecular markers of resistance to sulphadoxine-pyrimethamine in N’Zerekore. Malar J. 2007;6:54.

145. Maiga AW, Fofana B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

146. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45(1):1453–61.

147. Ursing J, Kfoed PE, Rodrigues A, Blessborn D, Thoft-Nielsen R, Bjorkman A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2011;203(1):109–16.

148. Martensson A, Ngasala B, Martensson A, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

149. Ashley EA, Lwin KM, McGready R, Simon WH, Phaiphun L, Proux S, et al. Efficacy of resistance to sulphadoxine-pyrimethamine in N’Zerekore. Malar J. 2007;6:54.

150. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

151. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

152. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

153. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

154. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

155. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

156. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

157. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

158. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

159. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

160. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.

161. Martensson A, Ngasala B, Martensson A, Ngasala B, Ngasala B, Sagara I, Dembele D, Dara A, Traore OB, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg. 2012;87(1):23–8.
artermether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41(8):1079–86.

177. Hatz C, Soto J, Nothdurft HD, Zoller T, Weizel T, Loutan L, et al. Treatment of acute uncomplicated falciparum malaria with artesunate-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg. 2008;78(2):241–7.

178. White NJ. Anaemia and malaria. Malar J. 2018;17(1):371.

179. Zwang J, D’Alessandro U, Ndiaye J-L, Djimde AA, Dorsey G, Mårtensson AA, et al. Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa. BMC Infect Dis. 2017;17(1):443.

180. Calis JC, Phiri KS, Faragher EB, Brabin BJ, Bates I, Cuevas LE, et al. Severe anaemia in Malawian children. N Engl J Med. 2008;358(9):888–99.

181. Kho S, Qotrunnada L, Leonardo L, Andries B, Wardani P, Fricot A, et al. Hidden biomass of intact malaria parasites in the human spleen. N Engl J Med. 2021;384(21):2067–9.

182. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17(5):491–7.

183. Balkagala B, Fukuda N, Ikeda M, Katofo OT, Tachibana SI, Yamauchi M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021;385(13):1133–45.

184. Uwimana A, Ulmalis N, Venkatesan M, Sivigal SS, Zhou Z, Munyanzenza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21(8):1120–8.

185. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201(4):570–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.